Aclaris Therapeutics enters $46.7 million stock offering at $3.50 per share
On October 27, 2026, Aclaris Therapeutics entered an underwriting agreement to sell 7,785,714 shares of common stock at $3.50 each, plus pre-funded warrants for 6,500,000 shares, in an offering under an effective Form S-3 registration. The Company estimates net proceeds of about $46.7 million, with closing expected on October 28, 2026. Because the offering adds new shares and warrants, existing shareholders' ownership percentage could be diluted.
Key points
- 7,785,714 common shares offered at $3.50 per share
- Pre-funded warrants for 6,500,000 shares priced at $3.49999 each, with a $0.00001 exercise price
- Estimated net proceeds of about $46.7 million; closing expected October 28, 2026
- Underwriters include Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.